Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.85 |
| ▸ | S100A4 | P26447 | 2/20 | 0.78 |
| ▸ | BCHE | P06276 | 1/20 | 0.78 |
| ▸ | ACHE | P22303 | 1/20 | 0.78 |
| ▸ | CES1 | P23141 | 1/20 | 0.78 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.73 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.73 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.73 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.73 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GPR3 | P46089 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | BAX | Q07812 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8668444 | 0.92 | PTPRC (0.93) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL6940816 | 0.92 | PTPRC (1.00) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL229511 | 0.88 | PTPRC (0.93) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL30096355 | 0.88 | PTPRC (1.00) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL31615476 | 0.88 | PTPRC (0.93) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL2599395 | 0.88 | PTPRC (1.00) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL14344701 | 0.86 | PTPRC (0.66) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL6393406 | 0.86 | PTPRC (0.65) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL5156700 | 0.85 | PTPRC (0.89) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL6391559 | 0.85 | PTGS2 (0.69) | PTPRCS100A4BCHEACHECES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115006537-A | Compositions and uses of alpha-adrenergic agents | 利维申制药有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20180311499-A1 | Treatment of Dermatological Conditions via Neuromodulation | PALO ALTO INVESTORS | 2018-11-01 | — | — | US | disclosed |
| EP-2398764-B1 | METHOD FOR MANUFACTURING 2-AMINOBIPHENYLS | BASF SE (DE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2598146-A1 | METHODS TO IDENTIFY TARGETS AND MOLECULES REGULATING PURINOSOMES AND THEIR USES | Corning Incorporated (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015599-A1 | METHODS TO IDENTIFY TARGETS AND MOLECULES REGULATING PURINOSOMES AND THEIR USES | CORNING INCORPORATED (US) | 2012-02-02 | — | — | WO | disclosed |
| US-8101779-B2 | Enantioselective synthesis of (+) and (–)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2398764-A1 | METHOD FOR PRODUCING 2-AMINOBIPHENYLENE | BASF SE (DE) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094736-A1 | METHOD FOR PRODUCING 2-AMINOBIPHENYLENE | BASF SE (DE) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010075275-A1 | SELECTIVE RELEASE OF NON-RACEMIC MIXTURES OF TWO ENANTIOMERS FROM TABLETS AND CAPSULES | USWORLDMEDS LLC (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100087657-A1 | ENANTIOSELECTIVE SYNTHESIS OF (+) AND (-)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL]-1,3-DIAZACYCLOPENT-2-3ENE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087657-A1 | ENANTIOSELECTIVE SYNTHESIS OF (+) AND (-)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL]-1,3-DIAZACYCLOPENT-2-3ENE | CYP2E1, CYP2D6, CYP2C9 | PTPRC 2959/4885S100A4 4454/4885BCHE 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.